ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Artus® CMV PCR Test (CMV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01034709
Recruitment Status : Completed
First Posted : December 17, 2009
Results First Posted : August 20, 2014
Last Update Posted : August 20, 2014
Sponsor:
Information provided by (Responsible Party):
QIAGEN Gaithersburg, Inc

December 15, 2009
December 17, 2009
July 8, 2014
August 20, 2014
August 20, 2014
December 2009
September 2013   (Final data collection date for primary outcome measure)
a) CMV Viral Load [ Time Frame: 3 months ]
The CMV viral load was measured by both the artus CMV RG PCR test and the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at the investigational sites and then the percent agreement between the two tests was determined.
  • Medical Decision Point #1 - the decision point at which the initial response/non-response to antiviral therapy is assessed. [ Time Frame: 7 days after initiation of anti-viral therapy ]
  • Medical Decision Point #2 - the decision point at which termination of standard antiviral therapy is made. [ Time Frame: at termination of anti-viral therapy ]
Complete list of historical versions of study NCT01034709 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of the Artus® CMV PCR Test
Clinical Evaluation of the Artus® CMV RG PCR Test
Subjects with symptomatic CMV infection, who are enrolled in this clinical study, will be monitored during antiviral therapy.

The human Cytomegalovirus (CMV) is found in blood, tissues and nearly all secretory fluids of infected persons. Transmission can be oral, sexual, via blood transfusion, organ transplantation, intrauterine, or perinatal. Infection with CMV preadolescence frequently leads to an asymptomatic infection followed by a lifelong persistence of the virus in the body. Infection post adolescence typically leads to symptoms that resemble those of mononucleosis (e.g., fever, fatigue, hepatitis, etc.) In contrast, CMV infections in immune compromised patients can be life threatening. A major cause of virus-associated morbidity and mortality in solid organ transplantation patients is illness caused by CMV (i.e., CMV syndrome or CMV disease).

The risk of progressing to CMV disease post-transplant is strongly correlated with the serological status of the donor (D) and recipient (R); the highest risk group is R-/D+. Patients at risk for CMV disease can be managed either preemptively (i.e., patients are only treated with antiviral agents after evidence of CMV infection arises), or prophylactically (i.e., all patients are treated with antiviral agents regardless of CMV infection status). Monitoring of the CMV viral load of transplant patients during antiviral therapy provides an effective aid in the management of patients with CMV disease. The artus® CMV RG PCR test is a nucleic acid amplification-based assay for the quantitation of CMV DNA using PCR in the Rotor-Gene™ 6000 Instrument (also known as Rotor-Gene Q) with software version 2.0.2.3 or higher. In the present study the artus CMV RG PCR test result will be evaluated for its ability to safely and effectively monitor transplant patients during antiviral therapy and will be compared to the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Extracted DNA
Non-Probability Sample
The study population includes subjects that have received a kidney transplant, and that are hospitalized or that present to a hospital, clinic or physicians office for post-transplantation care and will be treated with ganciclovir and/or valganciclovir for symptomatic CMV infection.
Cytomegalovirus Infections
Not Provided
  • Symptomatic
    Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
  • Asymptomatic
    Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
111
216
June 2014
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subjects must have had a kidney transplant.
  2. Subjects that present at a hospital, clinic or physicians office for post-transplantation care.
  3. Subjects must be 18 years of age or older.
  4. Subjects providing informed consent.
  5. Subjects must have a CMV infection as demonstrated by a positive result by the site's CMV-PCR-Laboratory Developed Test (CMV-PCR-LDT)
  6. Subjects must be candidates for, and will be treated with ganciclovir and/or valganciclovir antiviral therapy.

Exclusion Criteria:

  1. Subjects wherein the HIV status is positive.
  2. Specimens with less than 1.0 ml EDTA plasma for artus testing.
  3. Subjects from whom samples were collected, handled and/or stored inappropriately and/or determined to be unsatisfactory for processing/testing with the artus CMV RG PCR test (for which an explanation is provided in the case of subject exclusion).

    EDTA plasma specimens that have been stored inappropriately which include the following storage conditions: whole blood that has been frozen; whole blood processed for plasma more than 24 hours after collection; plasma stored at room temperature for more than 24 hours or 4C for more than 5 days at -20C for more than 6 months; frozen plasma with more than two freeze thaw cycles;

    Extracted nucleic acid that has been stored inappropriately which include the following storage conditions: extracted DNA stored for more than 5 days at -20C, or longer than six months at -20C; frozen nucleic acid with more than two freeze/thaw cycles.

  4. Specimens that have been stored inappropriately for testing with that test used by the site to demonstrate a CMV infection. (A site specific memo will be provided to QIAGEN on appropriate specimen storage conditions.)
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01034709
C09-CMV-001
No
Not Provided
Not Provided
QIAGEN Gaithersburg, Inc
QIAGEN Gaithersburg, Inc
Not Provided
Not Provided
QIAGEN Gaithersburg, Inc
August 2014